Interestingly, we found that 22% of all recruited cRCC patients in our study were carriers of combined GSTM1-null, GSTT1-active, GSTA1 low-activity and GSTP1-variant genotype, suggesting that this combination of GST genotypes might be considered as „risk-carrying genotype combination” in clear cell RCC. Here, GSTM1 is linked to chromophobe renal cell carcinoma.